Enveric Biosciences (ENVB) Total Non-Current Liabilities (2015 - 2023)
Enveric Biosciences (ENVB) posted Total Non-Current Liabilities of $9.1 million for Q2 2023, up 127.39% sequentially from $4.0 million in Q4 2022, and up 149.37% YoY from $3.6 million in Q2 2022.
Enveric Biosciences (ENVB) Total Non-Current Liabilities (2015 - 2023) Analysis & Trends
Enveric Biosciences has reported Total Non-Current Liabilities for 9 years, with the latest figure at $9.1 million in Q2 2023.
- Quarterly Total Non-Current Liabilities rose 149.37% year-over-year to $9.1 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $9.1 million (up 149.37% YoY) and the FY2022 annual result came in at $4.0 million, up 138.42% from the prior year.
- Total Non-Current Liabilities grew to $9.1 million in Q2 2023 per ENVB's latest filing, from $4.0 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $11.2 million in Q3 2021 and troughed at $230377.0 in Q2 2019.
- A 5-year average of $3.7 million and a median of $3.6 million in 2022 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2019 and 2021: Total Non-Current Liabilities plunged 89.42% in 2019, then soared 1260.17% in 2021.
- Over 5 years, Total Non-Current Liabilities stood at $1.2 million in 2019, then decreased by 29.46% to $825248.0 in 2020, then surged by 103.09% to $1.7 million in 2021, then jumped by 138.42% to $4.0 million in 2022, then jumped by 127.39% to $9.1 million in 2023.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $9.1 million, $4.0 million, and $4.7 million for Q2 2023, Q4 2022, and Q3 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Enveric Biosciences | 5.66 Mn | -2.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 9.09 Mn |
| Dec 31, 2022 | 4.00 Mn |
| Sep 30, 2022 | 4.66 Mn |
| Jun 30, 2022 | 3.64 Mn |
| Mar 31, 2022 | 5.64 Mn |
| Dec 31, 2021 | 1.68 Mn |
| Sep 30, 2021 | 11.22 Mn |
| Jun 30, 2021 | 1.17 Mn |
| Mar 31, 2021 | 626,947.00 |
| Sep 30, 2020 | 825,248.00 |
| Jun 30, 2020 | 1.86 Mn |
| Dec 31, 2019 | 1.17 Mn |
| Sep 30, 2019 | 4.45 Mn |
| Jun 30, 2019 | 230,377.00 |
| Mar 31, 2019 | 4.64 Mn |
| Dec 31, 2018 | 4.19 Mn |
| Sep 30, 2018 | 2.94 Mn |
| Jun 30, 2018 | 2.18 Mn |
| Mar 31, 2018 | 2.28 Mn |
| Dec 31, 2017 | 2.38 Mn |